文献速递骨软组织肉瘤与黑色素瘤

胚胎型横纹肌肉瘤区域淋巴结受累的治疗与预后意义:欧洲儿童软组织肉瘤研究组报告

Therapy and prognostic significance of regional lymph node involvement in embryonal rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group.
PubMed 文献 · Eur J Cancer · 2022-06-25

该研究基于EpSSG RMS 2005方案纳入的1294例胚胎型横纹肌肉瘤(ERMS)患儿,其中143例存在区域淋巴结受累(N1)。N1患者5年无事件生存率和总生存率分别为65.2%和70.7%,低于N0患者的75.5%和86.3%;多因素分析显示淋巴结受累是独立预后因素,作者认为应将N1 ERMS归入高危组。

要点

  • N1 ERMS患者5年无事件生存率65.2%、总生存率70.7%,低于N0患者的75.5%和86.3%。
  • 多因素分析显示淋巴结受累及诊断时手术结果(IRS分组)为独立预后因素。
  • 在N1 ERMS患者中未发现与结局相关的治疗变量。

核心结论

  • 区域淋巴结受累是ERMS的独立预后因素,作者认为适合将N1 ERMS患者纳入高危组。
  • N1 ERMS患者特征与肺泡型横纹肌肉瘤不同,且结局优于肺泡型横纹肌肉瘤。
  • 在N1 ERMS患者中未发现与结局相关的治疗变量。

研究设计与样本

  • 2005年至2016年间,1294例ERMS患儿纳入欧洲儿童软组织肉瘤研究组(EpSSG)RMS 2005方案,其中143例为N1患者。
  • 治疗包括9个周期的异环磷酰胺、长春新碱和放线菌素D;部分患者若纳入随机研究还接受多柔比星和/或维持治疗。
  • 局部治疗计划在4个周期化疗后实施,包括手术切除宏观残留肿瘤和/或放疗(原发肿瘤及受累淋巴结)。

主要发现

  • N1患者年龄更大,肿瘤在大小、侵袭性、部位和可切除性方面均不利。
  • 与肺泡型横纹肌肉瘤不同,淋巴结受累在头颈部更常见,在肢体部位罕见。
  • N0患者5年无事件生存率为75.5%、总生存率为86.3%;N1患者分别为65.2%和70.7%。
  • 多因素分析显示淋巴结受累和诊断时手术结果(Intergroup Rhabdomyosarcoma Study分组)为独立预后因素。
  • 仅分析N1 ERMS患者时,未发现任何治疗变量与结局相关。

临床怎么用

  • 作者认为区域淋巴结受累是ERMS的独立预后因素,适合将N1 ERMS患者纳入高危组。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Regional lymph node disease (N1) is a component of the risk-based treatment stratification in rhabdomyosarcoma (RMS). The purpose of this study was to determine the contribution of nodal disease to the prognosis of patients with non-metastatic embryonal RMS (ERMS) and analyse their outcome by treatment received. PATIENTS AND METHODS: Between 2005 and 2016, 1294 children with ERMS were enrolled in the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 protocol, 143 patients with N1. Treatment comprised 9 cycles of ifosfamide, vincristine and dactinomycin. Some patients also received doxorubicin and/or maintenance if enrolled in the randomised studies. Local treatment was planned after 4 cycles of chemotherapy and included surgery to remove macroscopic residual tumour and/or radiotherapy (primary tumour and involved nodes). RESULTS: N1 patients were older and presented with tumours of unfavourable size, invasiveness, site and resectability. Unlike alveolar RMS, nodal involvement was more frequent in the head and neck area and rare in extremity sites. The 5-year event-free and overall survival were 75.5% and 86.3% for patients with N0, and 65.2% and 70.7% for patients with N1, respectively. The nodal involvement and the result of surgery at diagnosis (Intergroup Rhabdomyosarcoma Study group) were independent prognostic factors on multivariate analysis. Considering only patients with N1 ERMS, we were not able to identify any treatment variables which correlated with the outcome. CONCLUSION: In the case of nodal involvement, patients with ERMS present different characteristics and a better outcome than alveolar RMS. Regional nodal involvement is an independent prognostic factor in ERMS, therefore it is appropriate to include this population in the high-risk category.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ben-Arush M, Minard-Colin V, Scarzello G, et al. Therapy and prognostic significance of regional lymph node involvement in embryonal rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group. Eur J Cancer. 2022. PMID: 35763871. doi:10.1016/j.ejca.2022.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。